
(HealthDay News) – A gene-targeted personalized vaccine may delay the return of pancreatic cancer according to a small, but promising, trial. The mRNA vaccine, which was tailored to the genetic makeup of each patient’s tumor, worked in half of those who received it during 18 months of follow-up, researchers reported May 10 in the journal… read on > read on >